ViiV's Selzentry approved for treatment-naive HIV patients in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved a label expansion of ViiV Healthcare's CCR5 antagonist Selzentry (maraviroc) to include treatment-naive HIV patients.